Unlock instant, AI-driven research and patent intelligence for your innovation.

Chimeric antigen receptor and immune effector cell expressing chimeric antigen receptor

A chimeric antigen receptor and antibody technology, applied to genetically modified cells, cells modified by introducing foreign genetic material, animal cells, etc., can solve the problems of lack of specificity and not ideal, and achieve the effect of prolonging the survival time

Pending Publication Date: 2021-02-23
BOYUAN RUNSHENG PHARM (HANGZHOU) CO LTD
View PDF8 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, due to the lack of specific targets, the heterogeneity of solid tumors (different tumor cell phenotypes) and the tumor microenvironment, chimeric antigen receptor-mediated cell therapy is not ideal for the treatment of solid tumors. , so the development of chimeric antigen receptors for new targets is particularly critical to solve this problem

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Chimeric antigen receptor and immune effector cell expressing chimeric antigen receptor
  • Chimeric antigen receptor and immune effector cell expressing chimeric antigen receptor
  • Chimeric antigen receptor and immune effector cell expressing chimeric antigen receptor

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0116] Example 1: Detection of B7-H3 expression in tumors

[0117] In order to determine the expression of B7-H3 antigen in tumors, we first selected different tumor cell lines to test. At the same time, in order to further verify the expression of B7-H3 in primary tumors, we detected the expression of B7-H3 in slices containing multiple patient glioma tissues and normal tissues.

[0118] Method: Collect tumor cells and wash them three times with 1xPBS, then stain with B7-H3 antibody 15C11 on ice for 30 minutes, add APC-coupled goat anti-mouse secondary antibody after washing with 1xPBS, incubate at room temperature for 20 minutes, wash with 1xPBS and wash with The expression of B7-H3 on tumor cells was detected by flow cytometry.

[0119] Immunohistochemical staining: Sections of glioma tissues and normal tissues of multiple patients were used to detect the expression of B7-H3 in primary tumors with 15C11 antibody by immunohistochemical method.

[0120] Paraffin sections we...

Embodiment 2

[0122] Example 2: Cell Culture

[0123] The cell lines used in the present invention include 293T cells, which are cultured in IMDM medium containing 10% FBS, 1% glutaMAX, and 1% double antibody.

[0124] WM-266-4, SK-OV-3, LN-229, LN-18, U-87MG cell culture medium is in RPMI640 or DMEM with 10% FBS.

[0125] The retrovirus encoding GFP was prepared by transient transfection of 293T cells using a three-plasmid system (GFS-GFP, MMLV-gag-pol and pVSV-G. GFP-positive cells were prepared by infecting GFP-encoding retrovirus. Encoding Luciferase (Luc ) lentivirus was prepared by transiently transfecting 293T cells with Lenti-Luciferase, pspAX2 and pVSV-G, while the retrovirus encoding GFP-firefly luciferase (GFP-FFLuc) was prepared by GFS-GFP-FFLuc, MMLV-gag-pol and pVSV -G is prepared by transiently transfecting 293T cells. The tumor cell line used in mice is infected by the lentivirus encoding Luc or the retrovirus of GFP-FFLuc.

Embodiment 3

[0126] Example 3: Construction of Chimeric Antigen Receptor

[0127] A chimeric antigen receptor consists of a single-chain antibody region, a CD8α hinge region, a CD8α transmembrane region, a CD28 or 4-1BB co-stimulatory factor region, and a CD3ζ signal transduction region (see attached image 3 shown). The single-chain antibody region (scFV) of the chimeric antigen receptor is derived from the antibody against B7-H3 produced by each monoclonal hybridoma cell, and the amino acid sequence of the scFV is as shown in SEQ ID NO: 2, 14, 26, 38, 50, 62, 74, 86, 98 or 110. Chimeric antigen receptors are produced by gene synthesis and then cloned into retroviral vectors. After cloning, the correctness of the sequence was confirmed by sequencing.

[0128] Table 1. Sequence listing:

[0129] SEQ ID NO.1: Nucleic acid sequence of 15C11 single-chain antibody region

[0130] ATGGAGTTTGGGCTGAGCTGGCTTTTTCTTGTGGCTATTTTAAAAGGTGTCCAGTGCTCTAGAGACATCCAGATGACACAGAGCCCTAGCAGCCTGTCTGCCAGCGTGGG...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a chimeric antigen receptor targeting B7-H3, a nucleic acid molecule, a nucleic acid construct and the like encoding the chimeric antigen receptor targeting B7-H3, an immune effector cell expressing the chimeric antigen receptor targeting B7-H3, and application of the chimeric antigen receptor, the nucleic acid molecule, the nucleic acid construct and the like, and the immune effector cell. The chimeric antigen receptor targeting B7-H3 comprises an anti-B7-H3 binding structural domain, a hinge region, a transmembrane structural domain and a signal transduction structural domain. The invention also provides a composition and method for diagnosing, treating or preventing tumors expressing B7-H3.

Description

technical field [0001] The invention relates to the field of biomedicine, in particular to a chimeric antigen receptor targeting B7-H3, immune effector cells expressing the chimeric antigen receptor targeting B7-H3, and applications thereof. Background technique [0002] Cancer is one of the major diseases threatening human health. Common cancer therapies include radiotherapy, chemotherapy, targeted therapy, etc. Currently, immunotherapy is gradually entering mainstream therapy. Chimeric antigen receptor-mediated cell therapy is a type of immunotherapy. Chimeric antigen receptor-mediated T cell therapy targeting CD19 has achieved outstanding results in the treatment of B cell-related tumors. In some patients A cure was achieved (the tumor did not recur for 5 years). This prompted the FDA to approve chimeric antigen receptor-mediated T-cell therapy targeting CD19, and also promoted the rapid development of this therapy in the field of blood cancers. However, due to the lac...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K19/00C12N15/62C12N15/867C12N15/861C12N15/864C12N5/10A61K39/00A61P35/00A61P29/00A61P37/02
CPCC07K16/2827C07K16/30C07K14/7051C12N15/86C12N5/0636A61P35/00A61P29/00A61P37/02C07K2319/03C07K2319/33C07K2317/622C12N2510/00C12N2730/00043C12N2740/15043C12N2710/10043C12N2750/14143A61K39/464412A61K39/4611A61K39/464402A61K2239/47A61K39/4631C07K2317/73C07K2317/92C12N2740/16043C12N2740/13043A61K2039/80C07K2319/02A61K2039/505C07K2317/24C07K2317/53C07K2317/565
Inventor 孙闯冯新华赵斌
Owner BOYUAN RUNSHENG PHARM (HANGZHOU) CO LTD